Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03751410
Other study ID # UHS-2
Secondary ID U1111-1221-9732
Status Completed
Phase
First received
Last updated
Start date December 1, 2018
Est. completion date March 4, 2023

Study information

Verified date October 2023
Source University Hospital "Sestre Milosrdnice"
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Ibrutinib is an irreversible Bruton tyrosine-kinase inhibitor. In prospective studies, the ibrutinib efficacy in the treatment of various B-cell malignancies was established. Different ibrutinib side-effects have been found: diarrhea, arthralgia, infections, neutropenia, hypertension and increased risk of bleeding. Most of the mentioned side-effects were <3rd degree of severity and mostly didn't require dose adjustment or therapy discontinuation. Also, there was an increase in the incidence of atrial fibrillation (AFib) (6-16%). The AFib pathogenesis in this patient population is not clarified, but there are indications that ibrutinib inhibits phosphoinositide-3-kinase (PI3K)-Akt signal-pathway expressed in the myocytes. Regardless of the molecular pathogenesis, the clinical effect of ibrutinib on the myocardium, especially the left atrium, has not been studied. Hence, the aim of this study is to determine the ibrutinib effect on echocardiographic parameters of left atrial function. This study will be performed as a clinical, prospective, observational cohort study with a structured follow-up period of 12 months. All consecutive patients with hemato-oncologic diseases (including chronic lymphocytic leukemia, Mantle-cell lymphoma, Waldenstrom macroglobulinemia, etc.) prescribed with chronic ibrutinib therapy, who are able to understand and sign informed consent, will be enrolled. Primary objective is change of the left atrial function measured by the decrease of the left atrial strain deformation > 10%. Recruiting should not exceed 12 months with the minimal follow-up period of 12 months (24 months in total). Standardized statistical methods and tests will be done using SPSS Version 22.0 or newer. This unique study offers the possibility to show the long-term effect of chronic ibrutinib therapy on left atrial function assessed by transthoracic echocardiography. This observational data is needed to further refine the treatment of these patients and to prevent possible side-effects of ibrutinib which could endanger this specific patient population.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 4, 2023
Est. primary completion date March 4, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patients with haemato-oncologic diseases (including chronic lymphocytic leukemia, Mantle-cell lymphoma, Waldenstrom macroglobulinaemia, etc.) - patients prescribed with chronic ibrutinib therapy - patients who are able to understand and sign informed consent Exclusion Criteria: - patients with haemato-oncologic diseases who were prescribed with concomitant chemotherapy which can impact left atrial function - patients < 18 years old - patients with known or at initial echocardiography established dilated cardiomyopathy with left ventricular ejection fraction < 35% - patients with permanent atrial fibrillation and dilated left atrium or dilated both atriums - patients implanted with cardiac implantable electronic devices - patients who underwent cardiac surgery - patients with congenital heart diseases (surgically corrected or not) - patients with severe valvular pathology - patients with terminal renal disease - patients with chronic obstructive pulmonary disease - GOLD grade 4 - patients with life expectancy < 12 months - patients not willing to undergo clinical follow-up or sign informed consent - patients recruited in another clinical study

Study Design


Locations

Country Name City State
Croatia Sestre milosrdnice University Hospital Zagreb

Sponsors (1)

Lead Sponsor Collaborator
University Hospital "Sestre Milosrdnice"

Country where clinical trial is conducted

Croatia, 

References & Publications (11)

Boriani G, Corradini P, Cuneo A, Falanga A, Foa R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL. Practical management of ibrutinib in the real life: Focus on atr — View Citation

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schu — View Citation

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, — View Citation

Deeks ED. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia. Drugs. 2017 Feb;77(2):225-236. doi: 10.1007/s40265-017-0695-3. — View Citation

Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 2017 Jul;96(7):1175-1184. doi: 10.1007/s00277-017-2973-2. Epub 2017 Mar 24. — View Citation

Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016 Jul 7;128(1):138-40. doi: 10.1182/blood-2016-05-712828. Epub 2016 May 31. No abstrac — View Citation

Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes M, Nabhan C, Ali N, Schuster S, Carver J. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer — View Citation

O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. Safety Analysis of Four Randomized Controlled Studi — View Citation

Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, Massari F, Cortelezzi A. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol. 2018 Jun 11;11(1):79. doi: 10.1186/s13045-018-0626-0. — View Citation

Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15. — View Citation

Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCa — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary left atrial function change change of the left atrial function measured by the decrease of the left atrial strain deformation > 10% assessed by transthoracic echocardiography initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy
Secondary left ventricular ejection fraction change measurement of left ventricular systolic function change assessed by transthoracic echocardiography - method according to Simpson and Teicholz initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy
Secondary left ventricular diastolic function change measurement of left ventricular diastolic function change assessed by transthoracic echocardiography (E/A and E/E') initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy
Secondary left atrial volume change 2D and 3D left atrial volume change assessed by transthoracic echocardiography + left atrial dimension in PLAX and 4 chamber projection initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy
Secondary P wave duration change P wave duration and PQ interval duration change assessed in 12-lead electrocardiogram (in milliseconds) initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy
Secondary left atrial pump function change left atrial ejection fractionchange assessed by transthoracic echocardiography (doppler strain measurement method) initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy
Secondary atrial fibrillation incidence incidence of paroxysmal atrial fibrillation assessed by symptoms + ECG or 24-hours Holter-ECG initial measurement, 3 months, 6 months and 12 months after initiation of ibrutinib therapy
See also
  Status Clinical Trial Phase
Completed NCT04083924 - Preclinical Medical Student Echocardiography Training American Society of Echocardiography Curriculum N/A
Recruiting NCT05778500 - Algorithms to Improve the Accuracy of the Echocardiographic Report
Completed NCT04925245 - Clinical Reminder to Improve Appropriateness of Echocardiography N/A
Completed NCT02000492 - Frequent Ballgames Training for 9-11 Year Old Schoolchildren N/A
Recruiting NCT05055089 - Short- and Medium-term Results of New Generation Aortic
Completed NCT04334733 - The Impact of Preprocedural Animation About Echocardiography Display and Kaleidoscope Display on Anxiety in Children N/A
Recruiting NCT06106178 - A Novel Serious Game as an Alternative for Teaching Basic Point-of-Care Transthoracic Echocardiography Skills N/A
Completed NCT05103189 - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension N/A
Completed NCT03221205 - Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients N/A
Not yet recruiting NCT03638245 - Evaluation of the Fetal MPI in Abnormal Cardiotocography Cases in 3rd Trimester of Pregnancy and Fetal Outcome.
Recruiting NCT04395014 - Echocardiographic Assessment of Ventricular Strain During a Healthy Pregnancy in the First, Second, and Third Trimester.
Withdrawn NCT03133962 - Evaluation of the Contribution of the Ultrasound Tracking and the Positioning of the Distal End During the Implantation of Implantable Chamber or Long-lasting Venous Catheter N/A
Completed NCT04366453 - Evaluation of LVEF by a New Automatic Evaluation Tool in a Pocket Ultrasound Scanner N/A
Recruiting NCT05462301 - Normal Reference Range for Neonatal Echocardiography
Withdrawn NCT04810520 - Live Stream of Prehospital point-of Care Ultrasound by Air Rescue Physicians
Recruiting NCT03464591 - Cardiac Speckle Tracking Myocardial Strain Balance
Completed NCT04419662 - Evaluation of Patients After Cardiac Surgery: Novel Ultrasound Parameters for Quantification of Renal Perfusion & Analysis of Phenylephrines' Effect on Invasive Haemodynamics and Echocardiographic Measures Phase 4
Completed NCT00730964 - A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. Phase 4
Completed NCT06330103 - Efficacy of AI EF Screening by Using Smartphone Application Recorded PLAX View Cardiac Ultrasound Video Clips N/A
Not yet recruiting NCT05306730 - Echocardiography by Non-cardiologist in Early Management of Patients With Chest Pain N/A